DEA schedule
Is adalimumab a controlled substance?
Federal schedule for adalimumab from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Adalimumab is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and adalimumab is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted adalimumab?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 49 prescription listings from 9 labelers, none with a DEA schedule |
| DEA controlled substances list | adalimumab is not on the list |
Adalimumab NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 61314-391 | Adalimumab | injection, solution | 10 mg/.1mL | Sandoz Inc | None |
| 61314-332 | Adalimumab | injection, solution | 20 mg/.2mL | Sandoz Inc | None |
| 61314-327 | Adalimumab | injection, solution | 40 mg/.4mL | Sandoz Inc | None |
| 61314-325 | Adalimumab | injection, solution | 80 mg/.8mL | Sandoz Inc | None |
| 83457-186 | Adalimumab-bwwd | solution | 40 mg/.4mL | Cordavis Limited | None |
| 83457-187 | Adalimumab-bwwd | solution | 40 mg/.4mL | Cordavis Limited | None |
| 55513-413 | AMJEVITA | injection | 10 mg/.2mL | Amgen, Inc | None |
| 55513-399 | AMJEVITA | injection | 20 mg/.2mL | Amgen, Inc | None |
| 72511-399 | AMJEVITA | injection | 20 mg/.2mL | Amgen USA Inc. | None |
| 84612-399 | AMJEVITA | injection | 20 mg/.2mL | Nuvaila Limited | None |
| 55513-411 | AMJEVITA | injection | 20 mg/.4mL | Amgen, Inc | None |
| 55513-479 | AMJEVITA | injection | 40 mg/.4mL | Amgen, Inc | None |
| 55513-482 | AMJEVITA | injection | 40 mg/.4mL | Amgen, Inc | None |
| 72511-479 | AMJEVITA | injection | 40 mg/.4mL | Amgen USA Inc. | None |
| 72511-482 | AMJEVITA | injection | 40 mg/.4mL | Amgen USA Inc. | None |
| 84612-479 | AMJEVITA | injection | 40 mg/.4mL | Nuvaila Limited | None |
| 84612-482 | AMJEVITA | injection | 40 mg/.4mL | Nuvaila Limited | None |
| 55513-400 | AMJEVITA | injection | 40 mg/.8mL | Amgen, Inc | None |
| 55513-410 | AMJEVITA | injection | 40 mg/.8mL | Amgen, Inc | None |
| 72511-400 | AMJEVITA | injection | 40 mg/.8mL | Amgen USA Inc. | None |
| 55513-480 | AMJEVITA | injection | 80 mg/.8mL | Amgen, Inc | None |
| 55513-481 | AMJEVITA | injection | 80 mg/.8mL | Amgen, Inc | None |
| 72511-481 | AMJEVITA | injection | 80 mg/.8mL | Amgen USA Inc. | None |
| 84612-481 | AMJEVITA | injection | 80 mg/.8mL | Nuvaila Limited | None |
| 50090-6707 | HADLIMA | solution | 40 mg/.4mL | A-S Medication Solutions | None |
| 78206-186 | Hadlima | solution | 40 mg/.4mL | Organon LLC | None |
| 78206-187 | Hadlima | solution | 40 mg/.4mL | Organon LLC | None |
| 50090-6705 | HADLIMA | solution | 40 mg/.8mL | A-S Medication Solutions | None |
| 50090-6706 | HADLIMA | solution | 40 mg/.8mL | A-S Medication Solutions | None |
| 78206-183 | Hadlima | solution | 40 mg/.8mL | Organon LLC | None |
| 78206-184 | Hadlima | solution | 40 mg/.8mL | Organon LLC | None |
| 78206-185 | Hadlima | solution | 40 mg/.8mL | Organon LLC | None |
| 61314-509 | HYRIMOZ | injection, solution | 10 mg/.1mL | Sandoz Inc | None |
| 61314-476 | HYRIMOZ | injection, solution | 20 mg/.2mL | Sandoz Inc | None |
| 83457-108 | HYRIMOZ | injection, solution | 20 mg/.2mL | Cordavis Limited | None |
| 61314-473 | HYRIMOZ | injection, solution | 40 mg/.4mL | Sandoz Inc | None |
| 83457-100 | HYRIMOZ | injection, solution | 40 mg/.4mL | Cordavis Limited | None |
| 83457-101 | HYRIMOZ | injection, solution | 40 mg/.4mL | Cordavis Limited | None |
| 83457-102 | HYRIMOZ | injection, solution | 40 mg/.8mL | Cordavis Limited | None |
| 83457-103 | HYRIMOZ | injection, solution | 40 mg/.8mL | Cordavis Limited | None |
Showing 40 of 49 listings.
Questions
Is adalimumab a controlled substance?
No. Adalimumab is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and adalimumab is not on the DEA controlled substances list.
Is adalimumab a narcotic?
No. Adalimumab is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is Tumor Necrosis Factor Blocker.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.